his research group from Italy looked at the rate of relapse following
a change of treatment to fingolimod from natalizumab in 3 patients with
relapsing-remitting MS. Fingolimod was started 3-4 months after
natalizumab was stopped to help immune surveillance reconstitution and
reduce the risk of postnatalizumab MS reactivation. The three patients
developed severe MS reactivation 16 days, 19 days and 6 days after
These cases suggest that fingolimod is not
effective in controlling rebound, when started 3-4 months after
natalizumab cessation. More experience is needed to decide on the
correct timing of switching patients from natalizumab to fingolimod.
Authors: Centonze D, Rossi S, Rinaldi F, Gallo P.
Source: Neurology. 2012 Oct 3. [Epub ahead of print]
Read the abstract